Summaries for patients. Cost-effectiveness of a vaccine to prevent herpes zoster (shingles) in older adults.
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D003198:Computer Simulation; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003662:Decision Theory; D005260:Female; D006562:Herpes Zoster / Q000453:epidemiology / Q000517:prevention & control*; D014645:Herpesvirus 3, Human / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000453:epidemiology / Q000517:prevention & control*; D019057:Quality-Adjusted Life Years
D022283:Herpesvirus Vaccines